ArriVent Debuts on Nasdaq
29 Jan 2024
US$ 19.00
ArriVent BioPharma Inc (ArriVent), a clinical-stage biopharmaceutical company backed by Lilly Asia Ventures, Hillhouse...
Related Publications
Keppel Ltd has raised an aggregate of around US$1.5 bn in new commitments for its two infrastructure funds and a ......
Vision Knight Capital has led the series C financing round of Panex WD International Group (Panex) for an ......
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.